Priority Review in China for Pharnext's PXT3003

Pharnext S.A.S. (Euronext:ALPHA) said China's State Drug Administration granted Priority Review to an NDA for PXT3003 to treat Charcot-Marie-Tooth 1A (CMT1A) disease.

GeneNet Co. Ltd. (Tianjin, China), a JV between Pharnext and Tasly Pharmaceutical Co. Ltd. (Shanghai:600535), submitted the NDA in December 2017. The JV has commercialization rights to PXT3003 to treat CMT1A in China, including Hong Kong and Macau, and Taiwan (see BioCentury, May 12, 2017)...